Project description
Revolutionising skin cancer diagnostics
French company DAMAE Medical is developing new dermatological diagnostics based on a disruptive line-field confocal optical coherence tomography technology in a hand-held imaging device. The device captures in situ images of the skin layers with cellular resolution. It provides accurate diagnosis, thus minimising biopsies of benign lesions and improving detection of melanoma and non-melanoma skin cancers. Simultaneously, DAMAE is developing software to assist dermatologists with image interpretation and for telepathology and patient services. The company has completed the feasibility phase, resulting in a prototype of the technology and a consolidated atlas of skin cancer clinical images. The main objective of current phase 2 of the EU-funded OCTAV project is to achieve market assessment, clinical validation and regulatory approval.
Objective
French SME-company DAMAE Medical is facing skin cancer worldwide issue by developing the OCTAV Project, a new approach to
dermatological diagnostic based on a disruptive Line-field Confocal Optical Coherence Tomography (LC-OCT) technology, in a novel
hand-held imaging device.
OCTAV is designed to capture in situ images of the skin layers with a cellular resolution. It is used in conjunction with dermoscopy to
provide more accurate diagnosis, leading to fewer biopsies of benign lesions and earlier detection of melanoma (clinical use 1) and
non-melanoma skin cancers (clinical use 2). It may also guide the surgery to provide more accurate presurgical margins (clinical use
3), preventing unnecessarily large scars and reducing the risk of recurrence.
Correlatively, DAMAE is developing a full software solution, based on a data storage cloud-platform, a computer-aided software
designed to assist dermatologists with OCTAV image interpretation, as well as telepathology and patient services.
OCTAV device will initially be used by clinicians as a routine easy-handling diagnostic device in public practices (market segment 1).
Implementation of OCTAV software will enable its adoption by a much larger market, consisting of private practices dermatologists
(market segment 2). The approach will contribute to the development of skin cancer risk patient awareness, while changing the
current paradigm through a timely, performant, and non-invasive approach, and releasing the financial burden on the healthcare
system.
Project OCTAV has successfully completed in 2017 a feasibility phase covered by the SME Instrument Phase 1, resulting in a TRL6
prototype of the technology and a first consolidated atlas of skin cancer clinical images. The main objective of this Phase2 is to
scaleup
the OCTAV solution to TRL9 through industrialization activities and by achieving a definitive market assessment, the clinical
validation and the regulatory approval, before deploying the approach worldwide.
Fields of science
Keywords
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
91400 Orsay
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.